Summary
Background
Bioavailability of fat–soluble vitamins from conventional oral supplements is insufficient in some conditions in which fat digestion and absorption are chronically impaired (e. g. cystic fibrosis).
Aim of the study
We used a water–soluble form of fatsoluble vitamin E (AQUANOVA® solubilisate) to create a nutritional supplement (NS) in the form of vitaminized gummi bears (with micellised water–soluble α–tocopheryl acetate (100 IU) and 400 mg crystalline vitamin C). We assessed the bioavailability of the NS in comparison to conventional preparations.
Methods
The trial consisted of three study days (d0: NS sucked; d10: NS swallowed; d20: reference products swallowed). A total of 14 subjects (6 male/8 female), aged 25.3 (22.7–35.3) years, BMI 24.3 (19.0–31.7) kg/m2 participated in the study. They had blood samples drawn after fasting for ≥12 hours and then 1, 5, 15, 30, 60, 120, 180, 240, 300 and 320 minutes after ingesting the vitamins. HPLC and a colorimetric method were used to determine vitamin E and vitamin C, respectively. Areas under the curve (AUC0–320min) and maximum increases in plasma concentrations (Δ concentration) were calculated to assess bioavailability.
Results
The AUCs0–320min of α–tocopherol from d0 were significantly larger (p = 0.016) when compared to d20. Moreover, the maximum increase in α–tocopherol plasma concentrations was significantly higher for d0 (p = 0.023) and d10 (p = 0.002) when compared to d20.
Conclusions
Short–term bioavailability of AQUANOVA® micellised fat–soluble vitamin E from our NS was significantly higher than from regular supplements. The NS will now be tested for its clinical efficacy in a randomized double–blind controlled intervention trial with CF patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Traber MG, Kayden HJ, Green JB, Green MH (1986) Absorption of water-miscible forms of vitamin E in a patient with cholestasis and in thoracic duct-cannulated rats. Am J Clin Nutr 44:914–923
Sokol RJ, Heubi JE, Butler-Simon N, Mc-Clung HJ, Lilly JR, Silverman A (1987) Treatment of vitamin E deficiency during chronic childhood cholestasis with oral d-alpha-tocopheryl polyethylene glycol-1000 succinate. Gastroenterology 93:975–985
Traber MG, Schiano TD, Steephen AC, Kayden HJ, Shike M (1994) Efficacy of water-soluble vitamin E in the treatment of vitamin E malabsorption in short-bowel syndrome. Am J Clin Nutr 59:1270–1274
Harries JT, Muller DP (1971) Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Arch Dis Child 46:341–344
Back EI, Frindt C, Nohr D, Frank J, Ziebach R, Stern M, Ranke M, Biesalski HK (2004) Antioxidant deficiency in cystic fibrosis: when is the right time to take action? Am J Clin Nutr 80:374–384
Sokol RJ, Butler-Simon N, Heubi JE, Iannaccone ST, McClung HJ, Accurso F, Hammond K, Heyman M, Sinatra F, Riely C, Perrault J, Levy J, Silverman A (1989) Vitamin E deficiency neuropathy in children with fat malabsorption: Studies in cystic fibrosis and chronic cholestasis. Ann NY Acad Sci 570:156–169
Lancellotti L, D’Orazio C, Mastella G, Mazzi G, Lippi U (1996) Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation. Eur J Pediatr 155:281–285
Ihara H, Shino Y, Aoki Y, Hashizume N, Minegishi N (2000) A simple and rapid method for the routine assay of total ascorbic acid in serum and plasma using ascorbate oxidase and o-phenylenediamine. J Nutr Sci Vitaminol (Tokyo) 46:321–324
Ihara H, Matsumoto N, Shino Y, Aoki Y, Hashizume N, Nanba S, Urayama T (2000) An automated assay for measuring serum ascorbic acid with use of 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy, free radical and o-phenylenediamine. Clin Chim Acta 301:193–204
Bateman NE, Uccellini DA (1984) Effect of formulation on the bioavailability of retinol, D-alpha-tocopherol and riboflavine. J Pharm Pharmacol 36:461–464
Bateman NE, Uccellini DA (1985) Kinetics of D-alpha-tocopherol in a water soluble base in man. J Pharm Pharmacol 37:728–729
Soltani-Frisk S, Gronowitz E, Andersson H, Strandvik B (2001) Water-miscible tocopherol is not superior to fatsoluble preparation for vitamin E absorption in cystic fibrosis. Acta Paediatr 90:1112–1115
Winklhofer-Roob BM, van’t Hof MA, Shmerling DH (1996) Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. Am J Clin Nutr 63:722–728
Bauer KH, Frömming K-H, Führer C (1993) Pharmazeutische Technologie. Georg Thieme Verlag, Stuttgart
Traber MG, Thellman CA, Rindler MJ, Kayden HJ (1988) Uptake of intact TPGS (d-alpha-tocopheryl polyethylene glycol 1000 succinate) a water-miscible form of vitamin E by human cells in vitro. Am J Clin Nutr 48:605–611
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Back, E.I., Frindt, C., Oćenášková, E. et al. Can changes in hydrophobicity increase the bioavailability of α–tocopherol?. Eur J Nutr 45, 1–6 (2006). https://doi.org/10.1007/s00394-005-0556-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00394-005-0556-9